VA Federal Supply Schedule Service approves CTT as vendor for Calmare Pain Therapy Treatment

Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that the Department of Veterans Affairs' Federal Supply Schedule Service has accepted CTT's application to be an approved vendor for its Calmare^® Pain Therapy Treatment. This decision will enable CTT to sell Calmare Pain Therapy to physicians throughout the Federal government, with the expectation of significant sales in that market sector, which includes the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, the Bureau of Prisons, and State Veteran Homes.

"This approval by the Federal government will place our Calmare Pain Therapy Treatment on the Federal Supply Schedule, enabling physicians in the VA and DoD healthcare systems to purchase Calmare devices to treat our many veterans and wounded warriors who are suffering from debilitating pain every day," said John B. Nano, CTT's Chairman, President and CEO. "With as many as 60% of our returning war veterans suffering from significant pain, we are grateful to be able to offer these wounded warriors and their physicians a non-invasive pain relief option without the harmful, adverse side effects associated with powerful opioids, such as morphine."

Calmare is being used to treat pain patients at universities including Virginia Commonwealth University's Massey Cancer Center, under the direction of Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit; the University of Wisconsin, Madison's Paul Carbone Cancer Center under the direction of Toby Campbell, M.D.; and the University of Miami's Pain Management Center, under the direction of Salahadin Abdi, MD, PhD, Professor and Chief, University of Miami Pain Management Center. Additionally, patients are being treated with Calmare at hospitals and clinics in Massachusetts, New York, Virginia, Florida, Connecticut, Rhode Island, and Utah, as well as in Italy, India, Greece, and Bangladesh. Calmare Pain Therapy successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies.

The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is currently manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales.